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Abstract
Osteoporosis occurs commonly in homocystinuria. The underlying pathobiochemical mechanism remains unclear: disturbed cross-lin­
king of collagen has been suggested but this hypothesis has not been fully tested, nor have studies on collagen synthesis been performed. 
We therefore used recently available noninvasive tests for collagen synthesis and cross-linking to examine 10 patients with homocystin­
uria. Synthesis of collagen type I and type III was not different from age-matched healthy controls as reflected by comparable plasma 
levels of carboxyterminal propeptide of type I procollagen (PICP) and of plasma levels of N-terminal propeptide of procollagen type III 
(PIIINP). Collagen type I cross-links expressed by serum carboxyterminal telopeptide of collagen type I (ICTP) were 1.14 ±  0.24 ¿ig/1 in 
the patient group versus 3.29 ±  0.32 f i g / I  in the control group. This significant reduction of cross-links in the group with homocystinuria 
did not correlate with serum homocysteine or homocysteie acid concentrations. Our data clearly indicate that the disturbed cross-linking 
hypothesis still holds and that the bone manifestations of homocystinuria are not due to deficient collagen synthesis.
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1. Introduction
Patients with homocystinuria develop osteoporosis, sub- 
luxation of the ocular lens, mental retardation and vascular 
disease; the overall risk of these patients developing osteo-
been reported to be 50% by age 16 [I]. 
McKusick first proposed that excess homocysteine 
interfere with the normal synthesis of collagen cross- 
[2] and some indirect evidence for this 
provided by the finding of increased acid solubility of 
collagen from skin biopsies in two out of four patients 
with homocystinuria [3]. Homocystinuric patients present­
ing with decreased precursor aldehydes of skin colk  
have been described [4].
A mechanism similar to that reported for D-penicilla- 
mine, which shows structural analogy with homocysteine, 
has also been proposed. D-penicillamine decreases collagen
by blocking lysyl- or hydroxylysyl aldehyde 
residues which are known cross-link precursors [5]. Inhibi-
Corresponding author. Fax: + 4 3  I 404003238.
tion of the formation of Schiff base bifunctional cross-links 
has been suggested as well [6]. In vitro studies have shown 
that homocysteine inhibits cross-linking and fibril forma­
tion of isolated collagen in solution although in relatively
concentrations [4]. This is not a specific finding as it 
known that other amino acids can inhibit fibril 
formation o f collagen at relatively low concentrations; an
of the amino groups of arginine 
with the earbonyl/aldehydic residues [7]. Although high
have been reported to
to
is
examnle is ì re ae
inhibit lysyl oxidase 
occur in vivo [8].
concentrations arc
The hypotheses mentioned above and in a recent review 
require confirmation. No in vitro or in vivo studies
investigating so far
and, in particular, no work has been reported examining
isis in vivo or in vitro. We therefore studied
collagen type I synthesis by measuring plasma carboxyter­
minal propeptide of type 1 procollagen (PICP). tmss-lin- 
ked carboxyterminal telopeptide of collagen type 1 (ICTP) 
and the synthesis of collagen type III as represented by the
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N-terminal propeptide of procollagen type III (PIIINP) in 
plasma.
We found normal tic parameters for collagens 
type I and III but a significant decrease of cross-linked 
carboxyterminal telopeptide of collagen type I in patients 
with homocystinuria.
¿¿M cysteic acid (Sigma) in 0 .1 M HC1 were added as 
internal standard, followed by the addition of 0.1 ml of 3
M NaBH4 in 0.1 M NaOH mixed with DMSO (2:1 v /v ) .  
To prevent foaming during the reduction step 30 /¿l of 
«-amylalcohol were used. After a 30-min incubation period 
at 50°C and protein precipitation with 500 ¡i\ of 6% 
perchloric acid, 500 /i\ of the supernatant were mixed with 
100 ixl of freshly prepared iodoacetic acid (0.1 M in 9.22
2. Patients and methods M borate buffer). the addition of 100 a\ of 3 M
2.1. Patients
Plasma of 10 patients with hyperhomocysteinemia were 
obtained from a group of patients treated at the University 
Hospital Nijmegen. Nine of them had cystathionine beta 
synthase deficiency and one had the thermolabile form of  
methylenetetrahydrofolate reductase deficiency [10]. Cys­
tathionine beta synthase deficiency was established by 
severely elevated levels o f  homocystein and methionine 
and decreased ( <  5% of normals) enzyme activity in 
fibroblasts. The clinical characterization is given in Table 
1 .
EDTA blood was drawn and centrifuged 10 min at 
3000 X g within 30 min and stored at — 20°C.
Plasma of 20 age-matched healthy subjects served as 
controls.
NaOH 200 /jl\ of the obtained solution were derivatized 
with 100 ¡x 1 o f  400 fxM o-phthalaldehyde solution as
described elsewhere [ 12].
100 - /a 1 aliquots were injected into the port o f the HPLC 
system consisting 
model 400 and a Spectroflow 980 fluorescence detector. 
The wavelengths used were 230 nm for excitation and 417 
nm for emission. The Shimadzu C-R6A Chromatopac 
integrator was used for data handling.
A C18 Kromasil 100 analytical (5 /¿m) column (250 X 
4.6 mm) was
2.2. Methods
to a second column of that kind 
with the dimensions of 1 5 0 X 4 .6  mm. The mobile phase 
consisted o f solvent A (water/sodium propionate 
b u ffe r /a c e to n itr i le  =  6 0 :3 0 :1 0 )  and so lvent B 
(water/acetonitrile/methanol =  45:30:25). The flow rate 
was 1.3 m l/m in  during 24 min, then 1.0 ml for 6 min, 1.3 
ml during 22 min and 1.4 m l/m in  during 10 min. Stan­
dards used in the experiments were homocysteine hydro­
chloride, homocysteic acid and cysteic acid, all from Sigma.
2.2.1. Determination o f plasma 
homocysteic acid levels
nne
For the HPLC determination the principle of Fermo 
with modifications to allow the concomitant detection of
2 2 2 I  m  I  A r f  t o f plasma parameters fo t
and cross-
Commercially available radioimmunoassays for plasma 
carboxyterminal propeptide KPICP, Orion Diagnostics),
Ihomocysteic acid was followed [11]. Briefly, 100 ¡i\ o f cross-linked carboxyterminal telopeptide of collagen 
distilled water (HPLC grade Merck, Germany) and 100 ¡x\ (ICTP, Orion Diagnostics) and N-terminal propeptide col- 
of 9 M urea were added to 100 ¡i\ of plasma. 10 ¡x\ of 2 lagen type III (PIIINP, Orion Diagnostics) were applied
Table 1
Clinical characterization of patients
Patient No.
M hp pp i im
Age Height (cm) Weight b(kg) Marfanoid t,'
At diagnosis a At study
J Height in the presence of kyphoscoliosis, 
r 5-MethyIenetetrahydrofotate reductase deficiency because of thermolability.
n .H H MPim a«M Tmnnin
Treatment
Vit B6
i m p M sm inauw
Folate Vit li 12
n i n B n i. B iw
'•aine
1 E53 4~f * * 31 m 188 80 « H M
2 M61 33 in 190 89 H~
3 B61 26 33 m 191 77 «
4 B 5 8 27 36 m 191 87 +
5 S25 61 65 f 165 11 56
6  V43 e 50 50 m 170 84
7 D 6 7 3 27 m 187 77 —
8 D66 4 28 m 184 84 —
9 U78 7 16 r 171 64 —■ + 4-
10 C62 31 31 f 180 63 4*
’* Treatment started since diagnosis except in patient 6 .
Height/weight at study.
Marfanoid because of dotichosienomelia, araclinodactyly or thorax deformation.
■I ƒ%!■
f"'».V S
f
x.'l-M l
n o n m i D n v i
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and the supplier’s instructions were followed. Table 3
Means and S.D. of parameters evaluated in the study
2.2.3. Statistical calculations
The Mann-Whitney ¿/-test was used for the comparison 
o f  groups and linear regression analysis for the correlation 
of data [13]. Statistical significance was accepted at the 
P < 0 .0 5  level.
HC
/xM / 1
HCA
jU.M/1
PICP
Mg/1
PIIINP
Mg/ 1
ICTP
Mg/1
Patients Means 126.7 8.6 155.3 3.84 1.14
S.D. 75.39 1.17 20.41 0.72 0.24
Controls Means 12.8 1 .53 154.8 3,735 3.29
S.D. 2.98 0.62 17.6 0.612 0.32
3. Results were significantly in
The results are listed in Tables 2 and 3.
Plasma homocysteine and homocysteic acid were signif­
icantly higher in the group with homocystinuria. There was
no correlation between homocyst(e)ine and homocysteic
patient group and undetectably low in half the plasmas 
examined.
There was no correlation between homoeyst(e)ine, ho­
mocysteic acid and any parameter of collagen metabolism
*L SS'
The collagen synthesis parameters for type 1 and type 
III collagen did not differ between controls and patients.
IICTP levels, the parameter for collagen
4. Discussion
Table 2
Results of plasma total homocysteine homocysteic acid and the plasma 
parameters for collagen metabolism and cross-li
Patient
No.
Homocyst(e)ine
ju.M/1
Homocysteic 
acid ju.M/ 1
PICP 11
Mg/ 1
PIIINP " 
Mg/1
ICTP L' 
Mg/1
1 E53 53 8 146 4.4 1.3
2M 61 41 9 152 4.2
3 B61 101 9 130 1 0 4W « —
4 B58 79 8 176 4.1 1.4
5 S25 238 9 184 5.1 1.2
6 V43 108 6 | 11 3.3 IWII'»
7 D67 90 8 166 0 0 M 1 /
8 D 66 199 10 173 4 0.8
9 V78 106 10 142 3 .3
10 C62 -»S'? 9 162 4.2 1
Controls
1 16 -> 144 4.2 3
~> 14 1 162 4.1 3.4
3 10 1 125 4.3 3.1
4 12 136 i  (i♦ V f 4
5 16 146 i  7 3.1
6 13 1 156 3 .1 * * •
7 18 2 170 i  n
8 7 1 172 4 %* * ÉW
9 10 n 180 4 3.4
10 11 1 173 4.1 3.5
11 11 4 m 142 3.4 3.6
12 P4 4m * 3 160 5.1 3 3 * J • ft *
13 14 1 136 4.2 3.2
14 
1 ^
16 
I ^ 1
142 3 3 % * » % * 
1 1
3 
1 11 D 
16
i D
15
1 JrJ 
162 3.6
4 .  1
2.9
17 16 186 3.2 3
18 12 2 170 4.1 3.1
19 8 1 164 4 "> q | *
20 10 1 141 4.1 •r * ♦ to •*
11 PICP reflecting collagen type I formation (carboxyterminal propeptide 
o f  procollagen type I).
l' PIIINP reflecting collagen type III formation (N-termimil propeptide of 
procollagen type III).
ICTP reflecting collagen type I cross-links (cross-linked carhoxylonui- 
nal telopeptide of collagen type I) |  undetectably low.
In this study, we have demonstrated normal parameters 
for collagen type I and III synthesis but decreased collagen 
cross-linking.
PICP is nearly an ideal analyte of collagen formation, 
as it is formed and set free in a stoichiometric relationship 
to the amount of type I collagen synthesized and deposited 
in the tissue. Furthermore, the antigen measured in serum 
is homogenous and of the same size as the authentic 
propeptide. Its elimination from serum takes places via 
mannose receptor-mediated endocytosis mainly by the en­
dothelial cells of the liver [14]. PICP is a reliable indicator 
for collagen synthesis, for example in bone formation;
examples are the increase of PICP in bone forming
metastasis of prostate cancer [15], the decrease of PICP in 
osteoporotic women [16], the decrease of PICP in osteoge­
nesis imperfecta [17] or the decrease following systemic
therapy [18]. In our s no difference
between plasma PICP of patients with homocystinuria and 
healthy probands was observed, although both compounds, 
homocysteine and homocysteic acid are toxic in higher 
concentrations and thus could have led to inhibition of 
bone collagen synthesis. PIIINP reflecting procollagen type 
III synthesis and studied as a minor collagen in bone but 
major collagen in skin, was unaffected as well.
ICTP is formed during the maturation of collagen fibres 
and representing type I collagen specific cross-links. This 
cross-linked carboxyterminal telopeptide of collagen type I 
is cleared by the kidneys. Collagen type I degradation 
results in increased serum levels of ICTP correlating with 
calcium kinetics [19] and bone histomorphometrie indices 
[20]; good examples are the increased ICTP in breast
cancer with bone-degrading metastasis, rheumatoid arthri­
tis with osteolysis [21] or multiple myeloma [22]. In our 
study a significant reduction of plasma ICTP was noted in 
the homoeystinuric subjects. However, no correlation be­
tween homocysteine or homocysteic acid levels and plasma 
ICTP was found. It is possible that, since homocysteine
162 B. Liibec et al. /  Biochimica et B iaphysica A d a  ¡315 ( 1996) 159—162
levels were much higher in the cases than controls, a 
threshold effect is operating rather than a dose
effect. Another possibility is that tissue rather than plasma 
homocysteine might correlate better with plasma ICTP.
The interpretation of these results on ICTP can be 
therefore only speculative. Based on the suggested mecha­
nism leading to osteoporosis in homocystinuria reduction 
of ICTP must be interpreted as measuring a collagen split 
product with reduced cross-linking, thus fully compatible 
with mechanisms listed in the introduction. The sulfhydryl 
residue of homocysteine is able to block reactive car- 
bonyles representing precursors of collagen cross-links [5]. 
It is therefore not surprising that serum cross-linked car- 
boxyterminal telopeptide of type I collagen is reduced in 
our homocystinuric patients and supports the hypothesis of 
deficient cross-linking in homocystinuria as first proposed 
by McKusick [2].
Reduction and subsequent cleaving of disulfide cross­
links of bone collagen by homocysteine would be an 
alternative mechanism for the development of osteoporosis 
but is not relevant as collagen type I does not contain 
significant cystein residues required for disulfide cross-lin­
king [23].
ICTP is considered a parameter either for collagen 
cross-linking or degradation; we found its reduction and 
inteipret the reduction as representing decreased collagen 
cross-links and not decreased degradation of collagen which 
would not fit into the disease, even if a cytotoxic effect of 
homocysteine was taken into consideration [24].
Our results show that reduced synthesis of collagens is 
not responsible for osteoporosis in homocystinuria and we 
provide data indicating reduced collagen cross-linking. We 
now propose studying further parameters of impaired 
cross-linking as, e.g., the determination of urinary pyridi-
noline cross- which in turn would strengthen
cross-linking hypothesis.
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